I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.
The Surrey Heartlands Medicines Safety Committee have agreed a resource to support practices in implementing the recommended actions in the recent - MHRA Drug Safety Update: Short-acting beta 2 agonists (SABA) (salbutamol and terbutaline): reminder of the risks from overuse in asthma.
Salbutamol Easyhaler or Ventolin Accuhaler are the locally preferred dry powder devices
Salamol MDI is the locally preferred salbutamol MDI device and should be used with a spacer device. It has a lower carbon footprint than the large volume MDIs such as Ventolin.
Branded prescribing of inhaler devices is recommended. See guidelines below
